WWOX

WWOX Full Name

WW domain containing oxidoreductase

WWOX Introduction

WWOX (WW domain containing oxidoreductase) is a highly conserved tumor suppressor gene located at the common chromosomal fragile site FRA16D, one of the most frequently altered regions in the human genome. Researchers and clinicians investigating cancer progression, treatment resistance, and disease prognosis have increasingly focused on WWOX because its expression is frequently reduced or lost in a broad spectrum of malignancies, including breast, pancreatic, lung, prostate, ovarian, and hepatocellular cancers. The WWOX protein contains two WW domains that mediate protein–protein interactions and a short-chain dehydrogenase/reductase (SDR) domain that contributes to cellular metabolic regulation. Recent studies have demonstrated that WWOX functions far beyond a conventional tumor suppressor, serving as an essential regulator of cellular homeostasis, genomic integrity, oxidative stress responses, mitochondrial activity, and signal transduction networks. Because alterations in WWOX expression are often associated with aggressive disease phenotypes and poor clinical outcomes, the gene has emerged as a promising biomarker for disease stratification and a potential target for future therapeutic intervention.

A growing body of evidence indicates that WWOX acts as a molecular scaffold that coordinates multiple signaling pathways involved in cell proliferation, apoptosis, differentiation, metabolism, and tissue development. Through direct interactions with transcription factors and signaling mediators such as HIF-1α, RUNX2, p53, SMAD proteins, and other regulatory molecules, WWOX helps maintain balanced cellular growth and prevents malignant transformation. Recent mechanistic studies have revealed that WWOX influences the choice between glycolysis and oxidative phosphorylation, thereby linking cellular metabolism to gene regulation and stress adaptation. Experimental models further demonstrate that loss of WWOX disrupts mitochondrial function, promotes reactive oxygen species accumulation, alters lipid and glucose metabolism, and impairs skeletal development. WWOX-deficient animal models exhibit severe metabolic abnormalities, osteoporosis-like phenotypes, neurodegeneration, and postnatal lethality, highlighting the gene's fundamental role in maintaining physiological function across multiple organ systems. These findings have expanded the relevance of WWOX beyond oncology and positioned it as a central regulator of metabolic and developmental health.

The clinical significance of WWOX extends across cancer, neurological disorders, and metabolic diseases. In oncology, reduced WWOX expression has been consistently linked to increased tumor invasiveness, epithelial–mesenchymal transition (EMT), cancer stem cell characteristics, metastatic potential, therapeutic resistance, and unfavorable survival outcomes. Recent pancreatic cancer studies have shown that WWOX loss cooperates with oncogenic KRAS activation to accelerate pancreatic intraepithelial neoplasia formation and pancreatic ductal adenocarcinoma progression through enhanced TGF-β/BMP signaling. Restoration of WWOX expression suppresses tumor growth, whereas genetic deletion promotes cancer cell survival and colony formation, underscoring its critical tumor-suppressive function. Beyond cancer, inherited WWOX mutations have been associated with severe neurodevelopmental disorders, epileptic encephalopathies, intellectual disability, and neurodegenerative processes. Human genetic studies also suggest links between WWOX variants and metabolic syndrome, dyslipidemia, obesity, and increased susceptibility to type 2 diabetes. Collectively, current research positions WWOX as a multifunctional disease-associated gene whose influence spans genome stability, metabolism, neural development, and cancer biology, making it an increasingly valuable target for biomarker discovery, precision medicine strategies, and next-generation therapeutic development.

Alternate Names for WWOX

WWOX; WW domain containing oxidoreductase; FOR; WOX1; FRA16D; SCAR12; HHCMA56; PRO0128; SDR41C1; D16S432E; WW domain-containing oxidoreductase; WW domain-containing protein WWOX; fragile site FRA16D oxidoreductase; short chain dehydrogenase/reductase family 41C, member 1;

• 1.Yang H, et al.; The Role of WWOX in Cancer Progression: Mechanisms and Therapeutic Potential. Cancers (Basel). 2025, 17(21):3435.
  2.Baryła I, et al.; WWOX and metabolic regulation in normal and pathological conditions. J Mol Med (Berl). 2022, 100(12):1691-1702.